Skip to main content
. 2016 Apr 22;5(6):e1160979. doi: 10.1080/2162402X.2016.1160979

Figure 7.

Figure 7.

Control of metastatic B16 melanoma lesions in the liver and lung via transfer of glycolipid-loaded DCs. (A) To induce liver metastasis, wild-type mice were inoculated in the spleen with 2.5 × 105 B16 melanoma cells. Five days later, mice were injected i.v. with 2 × 105 α-GalCer-loaded CXCL16hi or CXCL16neg BMDCs, or unloaded control BMDCs generated from wild-type mice (n = 14–20 per group). *p < 0.05 compared to unloaded DCs, †p < 0.05 compared to CXCL16neg DCs. (B) In independent experiments, 2 × 105 α-GalCer-loaded BMDCs generated from wild-type or CXCL16−/− mice were delivered 5 d after B16 inoculation (n = 9–10 per group). (C) To induce lung metastasis, wild-type mice were inoculated i.v. with 2.5 × 105 B16 melanoma cells. Three days later, mice were injected i.v. with 2 × 105 α-GalCer-loaded BMDCs generated from wild-type or CXCL16−/− mice (n = 4–6 per group). Liver and lung metastasis were examined 14 d after tumor cell inoculation using image analysis software to calculate tumor coverage. (D) Serum ALT levels were measured in tumor-bearing mice following administration of wild-type or CXCL16−/− DCs (n = 4–6 per group). *p < 0.05 compared to unloaded DCs, †p < 0.05 compared to CXCL16−/− DCs.